Two rounds this month put a sharp point on where robotics capital is actually flowing in 2026. AI2 Robotics, a Shenzhen-based maker of wheeled humanoid robots, raised roughly $735 million at a valuation approaching $3 billion in early July. LimX Dynamics separately raised $200 million in a pre-IPO round valuing the company at $2.21 billion, part of a broader wave of Chinese humanoid-robotics companies -- including category leader Unitree -- now actively pursuing public listings rather than staying private indefinitely.
The scale of these individual rounds sits inside an even larger trend: global robotics startups have raised $18.8 billion in 2026 so far, already ahead of the $15 billion raised across the entirety of 2025, with more than five months still remaining in the year. That's a category growing faster in dollar terms than most of the rest of venture capital, at a moment when overall US venture funding is itself hitting records driven overwhelmingly by AI.
“For global LPs, robotics is increasingly a category that requires genuine geographic diversification in sourcing, not just a US-centric humanoid-robotics thesis.”
What's notable is where that capital is concentrating. Earlier robotics-funding cycles were dominated by US and European humanoid-robot makers -- Figure AI, Agility Robotics, Apptronik -- capturing the bulk of venture attention and headline valuations. AI2 Robotics and LimX Dynamics' rounds, alongside Unitree's continued dominance, suggest Chinese humanoid-robotics companies are now commanding comparable or larger checks, backed by a domestic manufacturing base and supply chain that gives them a genuine cost advantage over Western competitors building similar hardware.
For US robotics investors, the scale of Chinese humanoid funding is a competitive signal worth taking seriously: AI2 Robotics' near-$3 billion valuation and LimX's IPO-track positioning suggest Chinese humanoid makers aren't just catching up on capability, they're now matching or exceeding US peers on capital access too. For global LPs, robotics is increasingly a category that requires genuine geographic diversification in sourcing, not just a US-centric humanoid-robotics thesis.
The bear case: humanoid-robotics valuations across both US and Chinese companies remain well ahead of any company's demonstrated commercial deployment at scale, and a category raising $18.8 billion against still-nascent real-world revenue carries real correction risk if commercialization timelines slip. What to watch next: whether LimX Dynamics and Unitree's pursuit of public listings actually reaches the market this year, which would be the first real test of whether public investors value Chinese humanoid-robotics companies at anything close to their private marks.